CD3 specific recombinant antibody

Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

53038875, 536 2353, 435 7021, 435271, C07K 1900, C07H 2104

Patent

active

059292121

ABSTRACT:
The invention provides recombinant antibody molecules comprising antigen binding regions derived from the heavy and/or light chain variable regions of a donor anti-CD3 antibody, e.g. OKT3, and which have anti-CD3 binding specificity, preferably of affinity similar to that of OKT3. The recombinant antibody is preferably a humanized antibody and may be a chimeric or CDR-grafted antibody. A method is disclosed for preparing CDR-grafted humanized antibodies in which, in addition to the CDR's, non-human antibody residues are preferably used at positions 23, 24, 49, 71, 73 and 78 of the heavy chain variable region and at positions 46, 48, 58, and 71 of the light chain variable region. The recombinant, especially the humanized, anti-CD3 antibodies may used for in vivo therapy or diagnosis.

REFERENCES:
patent: 5530101 (1996-06-01), Queen et al.
patent: 5535089 (1996-07-01), Queen et al.
Riechmann, et al. Nature 332:323-327 1988.
Queen, et al PNAS 86:10029-10033 1989.
Smith, et al Nature 337: 181-184 1989.
Jaffers, et al Transplantation 43(6) 572-578 1986.
Roberts et al, "Generation of Antibody with Enhanced Affinity and Specificity for its Antigen by Protein Engineering" Nature, 328(20):731-734, Aug., 1987.
Verhoeyen et al, "Reshaping Human Antibodies: Grafting an Antilysozyme Activity", Science, 239:1534-36 Mar. 25, 1988.
Levitt, et al., JMP, (1983) 168:595-620.
Waldmann, Science 252:1657-1662 (1991).
Harris et al., Tibtech 11:42-46 (1993).
Osband et al., Immunotherapy 11(6):193-195 (1990).
Dillman, Ann. Internal Med. 111:592-603 (1989).
Hird et al., Genes and Cancer (1990) chapter 17.
Cunningham et al., Tibtech 10: (1992).
Kettleborough et al., Protein Engineering $(7):773-783 (1991).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

CD3 specific recombinant antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with CD3 specific recombinant antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CD3 specific recombinant antibody will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-879852

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.